{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:40:31Z","timestamp":1770349231588,"version":"3.49.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702000, 82170612, 81672701"],"award-info":[{"award-number":["81702000, 82170612, 81672701"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010846","name":"Health and Family Planning Commission of Hubei Province","doi-asserted-by":"publisher","award":["WJ2019Q033"],"award-info":[{"award-number":["WJ2019Q033"]}],"id":[{"id":"10.13039\/501100010846","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2018ZX10302204"],"award-info":[{"award-number":["2018ZX10302204"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Knowing about cytokine profile contributes to clarify the underling immune mechanism of HBsAg seroclearance rate increase. This study aims to investigate cytokine changes during nucleos(t)ide analogues (NAs) and peginterferon-\u03b1 (Peg-IFN\u03b1) therapy and their impact on the HBsAg serologic response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 78 HBV DNA-negative chronic Hepatitis B (CHB) patients were studied after a lead-in phase of NAs with complete serum cytokines. Serum cytokines (IL-1\u03b2, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17 and TNF-\u03b1) were quantified by flow cytometry (FCM) every 24 weeks, before, during and at the end of NAs and Peg-IFN\u03b1 treatment. Clinical and laboratory data were also taken at the same time. Analysis was performed between cured and uncured groups characterized by HBsAg seroclearance. PBMCs samples from five patients (two in cured group and three in uncured group) were analyzed by FCM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HBsAg seroclearance was achieved in 30 (38,5%) patients defined as the cured group. In comparison to uncured individuals, cured patients showed similar expressions of serum IL-1\u03b2, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17 and TNF-\u03b1 during the treatment of NAs and Peg-IFN\u03b1. Compared with the uncured groups, IL-5 was remarkably increased in cured patients. IL-5 at weeks 24 and 48 were associated with HBsAg seroconversion (p=0.033 and 0.027, respectively). PBMCs sample analysis confirmed the predicted value of IL-5 in response to NAs and Peg-IFN\u03b1 treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>IL-5 at weeks 24 and 48 might be used as a biomarker for HBsAg seroclearance in NAs-experienced CHB patients treated with NAs combined with Peg-IFN\u03b1. More importantly, exploiting the expression of this cytokine may help to develop a better understanding of the immune pathogenesis of chronic HBV infection.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1104329","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T08:01:00Z","timestamp":1672905660000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon"],"prefix":"10.3389","volume":"13","author":[{"given":"Peipei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhishuo","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor Kudzai","family":"Chikede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dabiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziying","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiliang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoxia","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis b: Update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis b virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.livres.2020.02.005","article-title":"Gao Z.Functional cure of chronic hepatitis b: Efforts and prospects","volume":"4","author":"Mo","year":"2020","journal-title":"Liver Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis b: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"Members of the ICEHBVWG, chairs I-HSG, advisors I-HS, zoulim f. a global scientific strategy to cure hepatitis b","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29213","article-title":"A potent hepatitis b surface antigen response in subjects with inactive hepatitis b surface antigen carrier treated with pegylated-interferon alpha","volume":"66","author":"Cao","year":"2017","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv547","article-title":"Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis b","volume":"213","author":"Liang","year":"2016","journal-title":"J Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","article-title":"HBsAg loss with peg-interferon Alfa-2a in hepatitis b patients with partial response to nucleos(t)ide analog: New switch study","volume":"6","author":"Hu","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2014.0022","article-title":"Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption","volume":"27","author":"Chokshi","year":"2014","journal-title":"Viral Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701801","article-title":"Elevated hepatic CD1d levels coincide with invariant NKT cell defects in chronic hepatitis b virus infection","volume":"200","author":"Tan","year":"2018","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.13423\/j.cnki.cjcmi.007667","article-title":"Alterations of IFN-gamma and IL-4 of peripheral blood T cells in patients with chronic HBV infection","volume":"32","author":"Li","year":"2016","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2019.12.006","article-title":"CC motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells","volume":"19","author":"Zhuo","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2011.10.016","article-title":"Serum levels of interleukin-12 in various clinical states with hepatitis b virus infection","volume":"272","author":"He","year":"2012","journal-title":"Cell Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401659","article-title":"The effects of cytokines on spontaneous hepatitis b surface antigen seroconversion in chronic hepatitis b virus infection","volume":"194","author":"Wu","year":"2015","journal-title":"J Immunol"},{"key":"B15","first-page":"93","article-title":"Evaluation of serum IFN-\u03b3 and IL-5 levels in response to entecavir therapy in patients with chronic hepatitis b virus infection","volume":"25","author":"Badary","year":"2018","journal-title":"Egypt J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis b surface antigen in patients with chronic hepatitis b","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14629","article-title":"Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis b focusing on hepatitis b surface antigen clearance","volume":"47","author":"Qiu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201949568","article-title":"Interferon-induced degradation of the persistent hepatitis b virus cccDNA form depends on ISG20","volume":"22","author":"Stadler","year":"2021","journal-title":"EMBO Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.007","article-title":"Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis b","volume":"58","author":"Thimme","year":"2013","journal-title":"J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1988.tb00743.x","article-title":"T Cell-replacing factor (TRF)\/interleukin 5 (IL-5): molecular and functional properties","volume":"102","author":"Takatsu","year":"1988","journal-title":"Immunol Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(89)90098-7","article-title":"Rapid methods for purification of human recombinant interleukin-5 (IL-5) using the anti-murine IL-5 antibody-coupled immunoaffinity column","volume":"125","author":"Mita","year":"1989","journal-title":"J Immunol Methods"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.7.2264","article-title":"JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor alpha and betac subunit, respectively, and are activated upon IL-5 stimulation","volume":"91","author":"Ogata","year":"1998","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.11.040193.002441","article-title":"Origin of murine b cell lineages","volume":"11","author":"Kantor","year":"1993","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-020-00290-7","article-title":"Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis b after treatment with pegylated interferonalpha-2a","volume":"36","author":"Li","year":"2021","journal-title":"Virol Sin"},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jhep.2010.10.016","article-title":"Enhanced b-cell differentiation and reduced proliferative capacity in chronic hepatitis c and chronic hepatitis b virus infections","volume":"55","author":"Oliviero","year":"2011","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.148","article-title":"Regulatory T cells in the treatment of disease","volume":"17","author":"Sharabi","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nri2802","article-title":"Immunity and immunopathology to viruses: what decides the outcome","volume":"10","author":"Rouse","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25765","article-title":"Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis b virus infection in mice","volume":"56","author":"Stross","year":"2012","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J Hepatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis b","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.016","article-title":"OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection","volume":"70","author":"Jacobi","year":"2019","journal-title":"J Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121957","article-title":"PD-1 blockade partially recovers dysfunctional virus-specific b cells in chronic hepatitis b infection","volume":"128","author":"Salimzadeh","year":"2018","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1448329","article-title":"The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma","volume":"7","author":"DiDomenico","year":"2018","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1104329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T08:01:07Z","timestamp":1672905667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1104329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2022.1104329"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1104329","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"article-number":"1104329"}}